QURE
$74.64
Uniqure N.V.
($.36)
(.48%)
QURE
Earnings Whisper ®
N/A
2nd Quarter June 2019
Consensus:  ($0.75)
Revenue:  $1.53 Mil
Monday
Jul 29
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when QURE reports earnings?
Beat
Meet
Miss

Where is QURE's stock price going from here?
Up
Flat
Down
Stock chart of QURE
Analysts
Summary of analysts' recommendations for QURE
Score
Grade
Pivots
Resistance
$80.95
$78.97
$76.81

$74.83

Support
$72.67
$70.69
$68.53
Tweet
Growth
Description
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.